Provide enterprise telemedicine solutions for clinical care services. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (5% a year). Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.2× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
Sales run at $7.5M a year. A small number, but proof the product has real buyers.
There is $1.7M in the vault; even if every debt were paid off, $941K would remain.
A loss of $64K against $7.5M in annual sales.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.